Publications by authors named "Luc-Matthieu Fornecker"
Tafasitamab combined with lenalidomide was approved in Europe in 2021 for transplant-ineligible patients with relapsed/refractory diffuse large B-cell lymphoma. Approval was based on the L-MIND study, which demonstrated a 57.5% overall response rate (ORR), 41.
View Article and Find Full Text PDFAtezolizumab, obinutuzumab and venetoclax for the treatment of patients with relapsed/refractory B non-Hodgkin lymphoma: Final analysis of a phase II trial from the LYSA group.
Br J Haematol
July 2025
Developing new therapeutic regimens for relapsed/refractory (R/R) B non-Hodgkin lymphoma (NHL) patients remains a significant unmet clinical need. Our objective was to evaluate atezolizumab (ATE), obinutuzumab (OBI) and venetoclax (VEN) combination in patients with R/R NHL who had received at least one prior anti-CD20-containing immunochemotherapy regimen. We report here the final analysis of the phase II LYSA-promoted multicentre trial (NCT03276468) of this combination in follicular lymphoma (FL, n = 58), diffuse large B-cell lymphoma (DLBCL, n = 58) and marginal zone lymphoma (MZL, n = 20).
View Article and Find Full Text PDFThe GAINED study was a randomized phase 3 trial comparing obinutuzumab (G) with rituximab (R) plus ACVBP (doxorubicin, cyclophosphamide, and prednisone, combined with either vindesine or bleomycin) or CHOP14 (cyclophosphamide, doxorubicin, vincristine, and prednisone, administered on a 14-day schedule) induction, followed by positron emission tomography (PET)-guided consolidation. This post hoc analysis aimed to detail the outcomes of patients with primary mediastinal B-cell lymphoma (PMBL), verified through expert pathological review and the use of gene expression profiling (GEP) and next-generation sequencing. Of 620 centrally reviewed patients, 138 (22.
View Article and Find Full Text PDFDue to immunosuppressive treatment, COVID-19 vaccination is challenging in patients with B-cell lymphoma. We prospectively evaluated CD4, CD8 T-cell and serological responses to the COVID-19 mRNA vaccine in a cohort of patients treated for a B-cell lymphoma with anti-CD20 therapy. During lymphoma treatment, CD4, CD8, and CD19 cell dropped.
View Article and Find Full Text PDFArticle Synopsis
- A new community of heads of haematology departments has been formed to provide mutual support in response to challenges within the French hospital system.
- An inaugural seminar held in January 2023 laid the groundwork for this initiative, fostering connections and collaboration among participants.
- The community expanded in January 2024, involving a wider group of department heads, enhancing teamwork and resource-sharing to improve hospital management and operations.
Tafasitamab plus lenalidomide (TAFA-LEN) treatment relevance pre- or post-anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is debated. We analyzed patients with large B-cell lymphoma in the DESCAR-T registry treated with axi[1]cel or tisa-cel in ≥3rd line and TAFA-LEN before (n = 15, "TL-pre-CAR-T" set) or directly after (n = 52, "TL-post-CAR-T" set) CAR T-cell therapy. We compared TAFA-LEN v.
View Article and Find Full Text PDFHealth-related quality of life profile of newly diagnosed patients with Hodgkin and non-Hodgkin lymphomas: A real-world study including 3922 patients from the French REALYSA cohort.
Eur J Cancer
September 2024
Article Synopsis
- Advances in lymphoma treatment have made assessing health-related quality of life (HRQoL) crucial for newly diagnosed patients, yet there's limited information on their HRQoL profiles at diagnosis.
- A study involving 3922 adults with various lymphoma types utilized three validated EORTC questionnaires to evaluate HRQoL at diagnosis, achieving high completion rates between 84% and 88%.
- Findings highlighted significant impairments in global health status across lymphoma subtypes, with factors like gender, performance status, and B symptoms affecting HRQoL, providing valuable insights for future research and clinical practices.
Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): an open-label randomised, phase 3 study.
Lancet Haematol
June 2024
Article Synopsis
- Follicular helper T-cell lymphomas (TFHL) often have gene alterations affecting DNA methylation, and preliminary studies indicate that 5-azacitidine may be effective for patients with relapsed TFHL.
- This study compared the oral azacitidine treatment to typical therapies (like gemcitabine and bendamustine) in patients over 18 with relapsed or refractory TFHL across five European countries and Japan.
- The trial enrolled 86 patients, showing that those treated with azacitidine had a median progression-free survival of 5.6 months, significantly longer compared to 2.8 months for those receiving standard therapy.
The scarcity of malignant Hodgkin and Reed-Sternberg cells hampers tissue-based comprehensive genomic profiling of classic Hodgkin lymphoma (cHL). By contrast, liquid biopsies show promise for molecular profiling of cHL due to relatively high circulating tumour DNA (ctDNA) levels. Here we show that the plasma representation of mutations exceeds the bulk tumour representation in most cases, making cHL particularly amenable to noninvasive profiling.
View Article and Find Full Text PDFLong-term analysis of the RiBVD phase II trial reveals the unfavorable impact of mutations and hypoalbuminemia in older adults with mantle cell lymphoma; for the LYSA group.
Haematologica
June 2024
Article Synopsis
- - The phase II trial assessed the effectiveness of the RiBVD treatment (rituximab, bendamustine, velcade, and dexamethasone) in patients over 65 with mantle cell lymphoma (MCL), which resulted in a median progression-free survival of 79 months and overall survival of 111 months.
- - TP53 mutation status and albumin levels were identified as significant prognostic factors, with TP53 mutations linked to a higher risk of shorter progression-free survival and overall survival in the analyzed patient population.
- - A scoring system combining TP53 mutation status and albumin levels allowed differentiation of patient outcomes, indicating varying survival rates based on the presence of these factors, thus enhancing prognostic assessments
Article Synopsis
- Real-world data (RWD) are crucial for enhancing clinical trial (CT) findings, but challenges like data quality persist; the REALYSA study, launched in 2018, focuses on newly diagnosed lymphoma patients in France.
- A proof-of-concept analysis of 645 patients with diffuse large B-cell lymphoma (DLBCL) found high data completeness (<4% missing) and revealed good survival rates, with a median follow-up of 9.9 months showing 1-year event-free survival of 77.9% and overall survival of 90.0%.
- The study also assessed how well REALYSA's patient outcomes matched those from recent phase 3 trials (POLARIX and SENIOR), demonstrating
Article Synopsis
- The French hospital system is facing a crisis due to staff shortages, prompting department heads to seek collaborative solutions for maintaining patient care.
- A two-day seminar was held for fourteen hematology department heads, focusing on sharing experiences and fostering a community aimed at improving their hospitals.
- The participants expressed interest in expanding collaboration through regular seminars for department heads across various specialties, aligning with public service strategies to strengthen hospital departments and inspire broader change in the health system.
Objective: We undertook this study to analyze whole blood gene expression and to investigate the role of B cell genes in primary Sjögren's syndrome-related non-Hodgkin lymphoma (primary SS-NHL).
Methods: Peripheral whole blood samples were collected from 345 well-phenotyped patients with primary SS enrolled in the prospective Assessment of Systemic Signs and Evolution in Sjögren's Syndrome (ASSESS) cohort. Transcriptomic analysis was performed using human Clariom S Arrays (Affymetrix).
Article Synopsis
- Rituximab treatment is more effective than the 'watch and wait' approach for low-tumor burden follicular lymphoma, improving progression-free survival (PFS) but maintenance therapy raised concerns about resource use and patient adherence.
- A study compared intravenous (IV) rituximab and subcutaneous (SC) rituximab adminstration in patients, demonstrating better 4-year PFS rates in the experimental SC group (58.1% vs 41.2%).
- While high exposure to rituximab during the first three months led to improved response rates, time to next treatment (TTNT) and overall survival (OS) showed no significant differences between the two approaches.
Efficacy of a short sandwich protocol, methotrexate, gemcitabine, L-asparaginase and dexamethasone chemotherapy combined with radiotherapy, in localised newly diagnosed NK/T-cell lymphoma: A French retrospective study.
Br J Haematol
May 2023
Article Synopsis
- Extranodal NK/T-cell lymphoma, nasal type is a rare and aggressive cancer with a traditionally poor outlook, but a study explored a new treatment combining MGAD chemotherapy with targeted radiotherapy.
- In this study of 35 newly diagnosed patients, 91% achieved complete remission, with promising long-term survival rates of 71% at 2 years and 53% at 5 years.
- While some patients faced manageable side effects and a third relapsed within about 14.5 months, the short treatment approach showed effectiveness and tolerability for this challenging condition.
Article Synopsis
- Doctors studied a new treatment called BV-AVD for patients with a tough type of cancer called early-stage unfavorable Hodgkin lymphoma.
- * The study involved 170 patients who either received BV-AVD or a standard treatment called ABVD and checked how many were cancer-free after two rounds of treatment.
- * The results showed that more patients treated with BV-AVD were cancer-free compared to those who had ABVD.
Comparison of Short- and Long-Term Mortality in Patients with or without Cancer Admitted to the ICU for Septic Shock: A Retrospective Observational Study.
Cancers (Basel)
June 2022
Introduction: Cancer patients are at high risk of developing septic shock (SSh) and are increasingly admitted to ICU given their improved long-term prognosis. We, therefore, compared the prognosis of cancer and non-cancer patients with SSh. Methods: We conducted a monocentric, retrospective cohort study (2013−2019) on patients admitted to ICU for SSh.
View Article and Find Full Text PDFArticle Synopsis
- This study compared the effectiveness and safety of two treatment options for previously untreated follicular lymphoma: R-CHOP (rituximab with CHOP chemotherapy) and G-CHOP (obinutuzumab with CHOP chemotherapy).
- Data from 124 patients showed no significant difference in progression-free survival between the two treatments, although G-CHOP had higher rates of hematological toxicity and infusion-related reactions.
- The introduction of G-CHOP also led to significantly higher treatment costs, estimating an additional €30,000 per patient, suggesting no clear advantage of G-CHOP over R-CHOP in the current context.
Article Synopsis
- Stage IIB Hodgkin lymphoma (HL) patients with certain risk factors have a poor prognosis and are treated either as limited or advanced stage, with differing clinical trials comparing these treatment approaches.
- A study involving 148 patients showed that baseline total metabolic tumor volume (TMTV) and responses after two cycles of chemotherapy significantly influenced progression-free survival rates, with a median follow-up of 4.1 years showing PFS rates around 88%.
- The findings suggest that both upfront ABVD plus radiation therapy and upfront escBEACOPP without radiotherapy yield similar outcomes in these high-risk patients, while TMTV can effectively stratify their risk at baseline.
Clinical presentation, outcome, and prognostic markers in patients with intravascular large B-cell lymphoma, a lymphoma study association (LYSA) retrospective study.
Cancer Med
October 2022
Background: Intravascular large B-cell lymphoma (lVLBCL) is a very rare type of large B-cell lymphoma.
Methods: We conducted a retrospective study on IVLBCL patients treated from 2000 to 2016 in LYSA cooperative group centers.
Results: Sixty-five patients were identified in 23 centers.
Intensive chemotherapy followed by autologous stem cell transplantation in primary central nervous system lymphomas (PCNSLs). Therapeutic outcomes in real life-experience of the French Network.
Bone Marrow Transplant
June 2022
Article Synopsis
- * The study found that patients receiving treatment at first relapse and those treated with specific chemotherapy combinations faced poorer prognoses and higher treatment-related mortality, especially when SCAT was administered beyond the first relapse.
- * Overall survival rates were significant, with 5-year survival at 80% for first-line treatment and 50% for first-relapse treatment, indicating the importance of timing in ASCT to improve the benefit/risk ratio for different chemotherapy regimens.
Bendamustine-EAM versus R-BEAM after high-dose cytarabine-based induction in newly diagnosed patients with mantle cell lymphoma, a LYSA retrospective study.
Bone Marrow Transplant
April 2022
Cytarabine-based immuno-chemotherapy followed by autologous stem cell transplantation (ASCT) consolidation is standard of care for fit patients with Mantle Cell Lymphoma (MCL). BEAM (Carmustine, Etoposide, Aracytine, Melphalan) is among the most frequently used conditioning regimen. Studies comparing BEAM with Bendamustine-EAM (BeEAM) have suggested that patients treated with BeEAM have a better progression-free survival (PFS).
View Article and Find Full Text PDFOutcomes of refractory or relapsed Hodgkin lymphoma patients with post-autologous stem cell transplantation brentuximab vedotin maintenance: a French multicenter observational cohort study.
Haematologica
July 2022